Back to Browse Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 3

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

Authors Baptist Gallwitz

Published 10 May 2010 Volume 2010:3 Pages 117—124


Review by Single-blind

Peer reviewer comments 4

Baptist Gallwitz

Dept Medicine IV, Tübingen University, Otfried-Müller-Str, 10, 72076 Tübingen, Germany

Abstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration profile for once daily dosing. It is highly selective for DPP-4 in comparison to other enzymes of the dipeptidyl peptidase family. DPP-4 inhibitors elevate plasma concentrations of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This effect results in a glucose-dependent stimulation of insulin secretion and an inhibition of glucagon secretion without an intrinsic risk for hypoglycemia. In comparison to sulfonylureas and thiazolidinediones that promote weight gain, DPP-4 inhibitors are weight neutral. Saxagliptin has been approved by the FDA for the US and by the EMEA for Europe in 2009. Clinical trials showed a dose-dependent inhibition of DPP-4 by saxagliptin in doses ranging from 2.5 to 100 mg daily without serious side effects. Type 2 diabetic patients receiving 5 mg to 10 mg saxagliptin once daily had a significant lowering of HbA1c and glycemic parameters along with good tolerability and safety. Saxagliptin has demonstrated a good efficacy for glycemic parameters in various patient populations either in monotherapy or in combination with metformin and other oral antidiabetic drugs as well as a favorable cardiovascular profile. With its high selectivity for DPP-4 and its clinical and cardiovascular profile, saxagliptin is an attractive novel DPP-4 inhibitor.

Keywords: type 2 diabetes, diabetes therapy, DPP-4 inhibitors, incretin based therapy, GLP-1, saxagliptin

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Perioperative management of hemophilia patients receiving total hip and knee arthroplasty: a complication report of two cases

Tateiwa T, Takahashi Y, Ishida T, Kubo K, Masaoka T, Shishido T, Sano K, Yamamoto K

Therapeutics and Clinical Risk Management 2015, 11:1383-1389

Published Date: 15 September 2015

Romiplostim as a treatment for immune thrombocytopenia: a review

Chalmers S, Tarantino MD

Journal of Blood Medicine 2015, 6:37-44

Published Date: 19 January 2015

Social phobia in Parkinson’s disease: Prevalence and risk factors

Gultekin BK, Ozdilek B, Bestepe EE

Neuropsychiatric Disease and Treatment 2014, 10:829-834

Published Date: 21 May 2014

Temperament, character traits, and alexithymia in patients with panic disorder

Izci F, Gültekin BK, Saglam S, Koc MI, Zincir SB, Atmaca M

Neuropsychiatric Disease and Treatment 2014, 10:879-885

Published Date: 16 May 2014

Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A

Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S

Neuropsychiatric Disease and Treatment 2014, 10:865-867

Published Date: 16 May 2014

What’s in the pipeline? Drugs in development for autism spectrum disorder

Sung M, Chin CH, Lim CG, Liew HSA, Lim CS, Kashala E, Weng SJ

Neuropsychiatric Disease and Treatment 2014, 10:371-381

Published Date: 20 February 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al

International Journal of Nanomedicine 2010, 5:581-591

Published Date: 6 August 2010

Induced pluripotent stem cells: advances to applications

Timothy J Nelson, Almudena Martinez-Fernandez, Satsuki Yamada, et al

Stem Cells and Cloning: Advances and Applications 2010, 3:29-37

Published Date: 22 December 2009